Skip to main content
. 2021 Mar 6;13(5):1135. doi: 10.3390/cancers13051135

Figure 1.

Figure 1

Type I and II endometrial cancer (EC) cell response to dinaciclib, flavopiridol, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), and cisplatin exposure. Dose–response experiments are shown following 72 h of treatment with dinaciclib (blue), flavopiridol (orange), DRB (brown), and cisplatin (purple) in the Type I EC cell line (a) Ishikawa and the Type II EC cell lines (b) HEC-1A, (c) HEC-1B, and (d) HEC-50. Viability was measured using a RealTime-Glo MT cell viability assay and is normalized to vehicle controls.